Maurizio Fazio, MD, PhD

Maurizio Fazio is a Principal at Atlas Venture, a biotech Venture Capital firm dedicated to early-stage therapeutics investment and company creation, guided by a science-first and product-centric philosophy. His investments span a diverse range of therapeutic areas—from ALS (Trace Neuroscience) to complications of pregnancy (Comanche Biopharma)—with a primary focus on oncology and rare diseases. Maurizio currently serves as a board observer for Accent Therapeutics, AAVantgarde Bio, K36 Therapeutics, and as a board observer or director for several stealth-stage companies.

Before joining Atlas, Maurizio earned his PhD in Biological and Biomedical Sciences from Harvard Medical School, with dual concentrations in Cancer Biology and Developmental & Regenerative Biology. He conducted his doctoral research in the Zon Lab at Boston Children’s Hospital. Prior to his time in Boston, he was a Research Fellow in the Armstrong Lab at Memorial Sloan Kettering Cancer Center in New York. Originally from Italy, Maurizio earned his MD from Vita-Salute San Raffaele University in Milan.